Verbascoside (Synonyms: Acteoside, NSC 603831) |
Catalog No.GC13232
One-Click Copy Product Info
|
Verbascoside is an inhibitor of protein kinase C (PKC) isolated from Lantana camara, with an IC50 value of 25µM.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 61276-17-3
Sample solution is provided at 25 µL, 10mM.
Verbascoside is an inhibitor of protein kinase C (PKC) isolated from Lantana camara, with an IC50 value of 25µM [1]. Verbascoside can down-regulate the expression of TRPV3 Ca2+-dependent temperature-sensitive channel and inhibit the TAK-1/JNK/AP-1 pathway by phosphorylating SHP-1, thereby exerting anti-inflammatory effects [2]. Verbascoside has been widely used to improve the histological morphology and clinical symptoms of animal colitis and to prevent skin damage caused by ultraviolet radiation[3].
In vitro, Verbascoside treatment for 24 hours significantly inhibited the cell viability of MCF-7 cells and MDA-MB 231 cells, with IC50 values of 0.1270µM and 0.1597µM, respectively[4]. 100µM of Verbascoside pretreatment for 3 hours protected C6 cells from LPS/IFN-γ-induced cell death and inhibited the increase in lipid peroxidation levels[5]. Treatment with 16µM Verbascoside for 5 days significantly enhanced the cell viability of human β cells under endoplasmic reticulum stress conditions, regulated redox homeostasis and improved mitochondrial function[6].
In vivo, Verbascoside treatment via oral administration at a dose of 10mg/kg/day for 42 days improved the memory and spatial cognition abilities of APP/PS1 mice, and reduced the Aβ deposition and tau protein accumulation in the brain tissues[7]. Oral administration of a 60mg/kg dose of Verbascoside daily for 12 weeks significantly inhibited the atherosclerotic pathological progression in ApoE−/− mice fed with a high-fat diet, and improved liver lipid metabolism[8].
References:
[1] Herbert J M, Maffrand J P, Taoubi K, et al. Verbascoside isolated from Lantana camara, an inhibitor of protein kinase C[J]. Journal of Natural Products, 1991, 54(6): 1595-1600.
[2] Saha R, Majie A, Baidya R, et al. Verbascoside: comprehensive review of a phenylethanoid macromolecule and its journey from nature to bench[J]. Inflammopharmacology, 2024, 32(5): 2729-2751.
[3] Alipieva K, Korkina L, Orhan I E, et al. Verbascoside—A review of its occurrence,(bio) synthesis and pharmacological significance[J]. Biotechnology advances, 2014, 32(6): 1065-1076.
[4] Şenol H, Tulay P, Ergören M C, et al. Cytotoxic Effects of Verbascoside on MCF-7 and MDA-MB-231[J]. Turkish Journal of Pharmaceutical Sciences, 2021, 18(5): 637.
[5] Esposito E, Dal Toso R, Pressi G, et al. Protective effect of verbascoside in activated C6 glioma cells: possible molecular mechanisms[J]. Naunyn-Schmiedeberg's archives of pharmacology, 2010, 381(1): 93-105.
[6] Galli A, Marciani P, Marku A, et al. Verbascoside protects pancreatic β-cells against ER-stress[J]. Biomedicines, 2020, 8(12): 582.
[7] Wang C, Cai X, Wang R, et al. Neuroprotective effects of verbascoside against Alzheimer’s disease via the relief of endoplasmic reticulum stress in Aβ-exposed U251 cells and APP/PS1 mice[J]. Journal of Neuroinflammation, 2020, 17(1): 309.
[8] Lei P, Lü J, Yao T, et al. Verbascoside exerts an anti-atherosclerotic effect by regulating liver glycerophospholipid metabolism[J]. Food Science and Human Wellness, 2023, 12(6): 2314-2323.
| Cell experiment [1]: | |
Cell lines | MCF-7 cells |
Preparation Method | MCF-7 cells were seeded onto 96-well flat-bottomed microculture plates at a density of 5×103 cells/well in DMEM/F-12 medium supplemented with 10% fetal bovine serum, insulin at 4mg/ml, penicillin, and streptomycin (1%) at 37°C, in a 5% CO2 containing humidified chamber. The cells were allowed to adhere to the plates and were treated with various concentrations of Verbascoside (0.1, 0.5, 1, 10, 25, 50, and 100μM) for 24h, and the cell viability was measured. |
Reaction Conditions | 0.1, 0.5, 1, 10, 25, 50, and 100μM; 24h |
Applications | Verbascoside treatment significantly enhanced the cell viability of MCF-7 cells in a dose-dependent manner. |
| Animal experiment [2]: | |
Animal models | APP/PS1 mice |
Preparation Method | APP/PS1 mice (8 weeks old; 40.7-52.9g) were housed in a room with controlled temperature (21-23°C), humidity (40-60%), and lighting (12h light/dark cycle) and were supplied with water. Mice were randomly divided into two groups and given 0.4ml of normal saline (n=12) or 10mg/kg/day of Verbascoside (n=12) orally for 42 days. After the entire 42-day treatment period, all of the mice were euthanized via intraperitoneal injection of sodium pentobarbital (150mg/kg). Collect the brain tissues of mice for analysis. |
Dosage form | 10mg/kg/day for 42 days; p.o. |
Applications | Verbascoside treatment reduced the Aβ deposition and tau protein accumulation within the brain in APP/PS1 mice. |
References: | |
| Cas No. | 61276-17-3 | SDF | |
| Synonyms | Acteoside, NSC 603831 | ||
| Chemical Name | [(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate | ||
| Canonical SMILES | CC1C(C(C(C(O1)OC2C(C(OC(C2OC(=O)C=CC3=CC(=C(C=C3)O)O)CO)OCCC4=CC(=C(C=C4)O)O)O)O)O)O | ||
| Formula | C29H36O15 | M.Wt | 624.59 |
| Solubility | DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 30 mg/ml,PBS (pH 7.2): 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6011 mL | 8.0053 mL | 16.0105 mL |
| 5 mM | 320.2 μL | 1.6011 mL | 3.2021 mL |
| 10 mM | 160.1 μL | 800.5 μL | 1.6011 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 25 reference(s) in Google Scholar.)